DOCSLIB.ORG

Drugs and the Elderly Adult. Research Issues 32

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drugs and the Elderly Adult. Research Issues 32 DOCUMENT RESUME ED 245 177 CG 017 549 AUTHOR Glantz, Meyer D., Ed.; And Others TITLE Drugs and the Elderly Adult. Research Issues 32. INSTITUTION Metrotec Research Associates, Washington, D.C. SPONS AGENCY National Inst. on Drug Abuse (DHHS/PHS), Rockville, Md. REPORT NO OHMS-ADM-83-1269 PUB DATE 83 CONTRACT 271-80-3720 NOTE 326p. AVAILABLE FROMSuperintendent of Documents, U.S. Government Printing Office, Washington, DC 20402. PUB TYPE Information Analyses (070) -- Reference Materials - Bibliographies (131) EDRS PRICE MF01/PC14 Plus Postage. DESCRIPTORS Abstracts; Behavior Patterns; Drinking; *Drug Abuse; Drug Rehabilitation; Geriatrics; Gerontology; *Illegal Drug Use; *Older Adults; Patient Education; *Pharmacology; *Prevention; Psychological Patterns IDENTIFIERS Epidemiology ABSTRACT This book, on the nature and problems of inappropriate drug use by older adults, provides researchers and health practitioners with an up-to-date survey and overview of the literature on drug use, misuse, and abuse among the elderly. The volume provides abstracts of 100 selected scientific articles on the major topic areas in the field. The bibliography represents a fairly comprehensive listing of the United States literature with some relevant foreign materials. The abstracted publications, primarily scientific journal articles, are divided into eight sections preceded by a summary of the topic area presented in that section. The summaries highlight the research and related literature on that topic. The eight topics are:(1) an overview of drugs and the elderly; (2) epidemiology of drug use; (3) illegal drug use, older addicts, and the maturing-out hypothesis; (4) misuse of legal drugs; (5) pharmacology and therapeutics; (6) alcohol use and abuse; (7) consequences of drug use, misuse and abuse; and (8) prevention and treatment programs. (Author/JAC) *********************************************************************** * Reproductions supplied by EDRS are the best that can be made * * from the original document. * *********************************************************************** ;:Research Issues 32 ;Nt4 DRUGS AND THE ELDERLYADULT Edited by: Meyer D. Glantz, Ph.D. David M. Petersen, Ph.D. Frank J. Whittington, Ph.D. Al: 4-1.. -- 443ir : Ig* i 4" ' -..4...F..f; ;- ..- 1983 r 1, . I*;_3. 7 U.S. DEPARTMENT OF EDUCATION 4 el..L.: \ ; NATIONAL INSTITUTE OF EDUCATION .` EDUCATIONAL RESOURCES INFORMATION A ' .4;41 ''' . ,ZU- r ...... CENTER (ERIC) . ...... --r 7 4N;7144'. f',.._,,j1t,,c , )This document has been reproduced as i \ 4 received from the person or organization ,.. ,f.l.... originating it. .- Minor changes have been made to improve de: ii 7 N ....4-.., reproduction quality. .,.. ...;:.---,=._. Points of view or opinions stated in this docu ...., t..f.. .....- -'-i\, , ,..;- ment do not necessarily represent official NIE ..,y, 4,t,1)i.,,--, position or policy. ._ U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 2 RESEARCH ISSUES SERIES 1. Drugs and Employment 2. Drugs and Sex 3. Drugs and Attitude Change 4. Drugs and Family/Peer Influence 5. Drugs and Pregnancy 6. Drugs and Death 7. Drugs and Addict Lifestyles 8. A Cocaine Bibliography - Nonannotated 9. Drug Themes in Science Fiction 10. Drug Themes in Fiction 11. Predicting Adolescent Drug Abuse 12. Drug Abuse Instrument Handbook 13. Data Analysis Strategies and Cosigns or Substance Abuse Research 4. Drugs and Personality 15. Cocaine - Summaries of Psychosocial Research 16. The Lifestyles of Nine American Cocaine Users - Summary 17. Drugs and Crime 18. Drug Users and the Criminal Justice System 19. Drugs and Psychopathology 20. Drug Users and Driving Behaviors 21. Drugs and Minorities 22. Research Issues Update, 1978 23. International Drug Use 24. Perspectives on the History of Psychoactive Substance Use 25. Use and Abuse of Amphetamine and its Substitutes 26. Guide to Drug Abuse Research Terminology 27. Guide to the Drug Research Literature 28. Assessing Marijuana Consequences: Selected Questionnaire Items 29. Drugs and the Family 30. Public Health Issues and Drug Abuse Research 31. Women and Drugs 32. Drugs and the Elderly Adult Cover Illustration:Seated ad Manby Rembrandt van Rijn, 1630, Rosenwald Collection, National Gallery of Art, Washington, D.C. FromDrawings of Rembrandt,1965, Dover Publications, Inc. N.Y. 3 THE EDITOr, MF../Pe. D. Glantz, Ph.D., is a clinical research psychologist in the Division of Clinical Research of the National Institute on Drug Abuse. David M. Petersen, M.D., is a professor in the Department cf Sociology of Georgia State University. Frank J. Whittington, Ph.D., is an associate professor in the Department of Sociology of Georgia State University. This publication was partially developed by VETROTEC, Inc., Washington, D.C., under Contract No. 271-80-3720 from the National Institute on Drug Abuse. All material appearing in this volume is in the public domain and may be reproduced or copied without permission. Citation of the source is appreciated. The U.S. Government does not endorse or favor any specific commercial product, or commodity. Trade or proprietary names appearing in this publication are used only because they are considered essentialin the context of the studies reported herein. DHHS Publication No. (ADM)83-1269 Printed 1983 For Sale by the Superintendent of Documents. U.S. Government Printing OfficeWashington. D.C. 20402 Foreword The critical issues involved in drug use and abuse have generated many volumes analyzing the "problem" and suggesting "solutions."Research has been conducted in many disciplines and from many different points of view.The need to bring together and make accessible the results of these research investigations is becoming increasingly important.The Research Issues Series is intended to aid investigators by collecting, summarizing, and disseminating this large and dis- parate body of literature.The focus of this series is on critical problems in the field.The topic of each volume is chosen because it represents a challenging issue of current interest to the research community.As additional issues are identified, relevant research will be published as part of the series. Many of the volumes in the series are reference summaries of major empirical research and theo- retical studies of the last 15 years.These summaries are compiled to provide the readers with the purpose, methodology, findings, and conclusions of the studies in given topic areas.Other volumes are original resource handbooks designed to assist drug researchers.These resource works vary considerably in their topics and contents, but each addresses an area of emerging concern in the research world. Thomas J. Glynn, Ph. D. Division of Clinical Research National Institute on Drug Abuse Dan J. Lettieri, Ph.D. Division of Epidemiology and Statistical Analysis National Institute on Drug Abuse iii Preface Drugs and the Elderly Adult explores the nature and problems of inappropriate drug use by older adults, providing researchers and health practitioners with an up-to-date survey and overview of the literature on drug use, misuse, and abuse among the elderly.The volume is made up of an extensive bibliography, 100 abstracts of selected scientific articles, and eight integrative sum- maries of the major topic areas in the field. The bibliography is based on David Petersen and Frank Whittington's unpublished 1981 revision of their original selected bibliography (Petersen et al. 1979b) and was supplemented by bibliographies compiled by Meyer D. Glantz and Judith R. Vicary. The articles, book chapters, and books included in the bibliography are a fairly compre- hensive listing of the U.S. literature, with some relevant foreign materials.The bibliography focuses primarily on literature involving the misuse and abuse of licit and illicit drugs by the elderly, with related materials on their use of licit drugs, their use and abuse of alcohol, and an abridged listing of the related pharmacology literature. From this bibliography, the edi- tors, with the assistance of the Peer Review Panel, listed below, selected 100 publications to be abstracted. The abstracted publications, primarily scientific journal articles, are intended to be a collection of the most significant and representative research and theory on drugs and the elderly. Each abstract attempts to be a faithful representation of the original published report. The abstracts are divided into sections according to topics selected by the editors. Each of these eight sections is preceded by a summary of the topic area presented in that section.The summaries are intended to review the highlights of the research and related literature of that topic, to synthesize work in the area, and to present an overview.The summaries were written by the editors with the exception of the summaries on "Pharmacology and Therapeutics" and "Prevention and Treatment Programs," which were written by Peter P. Lamy and Judith R. Vicary, respectively. The abstracts are included in the volume followin:: the most relevant topic sum- mary; each set of abstracts is arranged in chronological order.References cited in the sum- maries are listed in the bibliography. Indexes designed to meet the needs and interests of drug researchers are included at the end of the volume. PEER REVIEW PANEL Carl Eisdorfer, M.D., Ph.D. George Maddox, Ph.D. Montefiore Medical Center Center for Aging Bronx, New York Durham,
Load more

Recommended publications
  • THIS WEEK ...We Focus on Some More Titles That Have Made an Impression on Eurogamer Readers, and Reveal Why
    Brought to you by Every week: The UK games market in less than ten minutes Issue 6: 14th - 20th July WELCOME ...to GamesRetail.biz, your weekly look at the key analysis, news and data sources for the retail sector, brought to you by GamesIndustry.biz and Eurogamer.net. THIS WEEK ...we focus on some more titles that have made an impression on Eurogamer readers, and reveal why. Plus - the highlights of an interview with Tony Hawk developer Robomodo, the latest news, charts, Eurogamer reader data, price comparisons, release dates, jobs and more! Popularity of Age of Conan - Hyborian Adventures in 2009 B AGE OF CONAN VS WII SPORTS RESORT #1 A This week we look at the Eurogamer buzz performance around two key products since the beginning of 2009. First up is the MMO Age of #10 Conan - a game which launched to great fanfare this time last year, but subsequently suffered from a lack of polish and endgame content. #100 Eurogamer.net Popularity (Ranked) Recently the developer, Funcom, attempted to reignite interest in the game by marketing the changes made in the build-up to its first anniversary - point A notes a big feature and #1000 Jul free trial key launch, while point B shows the Feb Mar Apr May Jun Jan '09 Age of Conan - Hyborian Adventures re-review which put the game right at the top of the pile earlier this month - whether that interest can be converted into subs is a different question, but the team has given itself a good Popularity of Wii Sports Resort in 2009 chance at least.
    [Show full text]
  • Genl:VE 1970 © World Health Organization 1970
    Nathan B. Eddy, Hans Friebel, Klaus-Jiirgen Hahn & Hans Halbach WORLD HEALTH ORGANIZATION ORGANISATION .MONDIALE DE LA SANT~ GENl:VE 1970 © World Health Organization 1970 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization. For rights of reproduction or translation of WHO publications in toto, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. Authors alone are responsible for views expressed in signed articles. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. © Organisation mondiale de la Sante 1970 Les publications de l'Organisation mondiale de la Sante beneficient de la protection prevue par les dispositions du Protocole n° 2 de la Convention universelle pour la Protection du Droit d'Auteur. Les institutions gouvernementales et les societes savantes ou professionnelles peuvent, toutefois, reproduire des donnees, des extraits ou des illustrations provenant de ces publications, sans en demander l'autorisation a l'Organisation mondiale de la Sante. Pour toute reproduction ou traduction integrate, une autorisation doit etre demandee a la Division des Services d'Edition et de Documentation, Organisation mondiale de la Sante, Geneve, Suisse.
    [Show full text]
  • SUMMER 2010 2 Casual Connect Summer 2010 Casual Connect Summer 2010 3 4 Casual Connect Summer 2010 Contents
    SUMMER 2010 2 Casual Connect Summer 2010 Casual Connect Summer 2010 3 4 Casual Connect Summer 2010 Contents Jessica Tams | Letter from the Director 7 Legal Studio Spotlight | Playrix Entertainment 8 59 Legal Issues Around Social Games | Dr. Andreas Lober and Olivier Oosterbaan Design & Production Compliance and Contracting (Part One) 62 Keeping It Real | Alisdair Faulkner and Jeff Sawitke Kenji Hisatsune | The Perfect Play 12 The Top Online Gaming Scams and How to Prevent Them Principles Driving PAC-MAN’s Success David Rohrl | Fundamentals of Social Game Design 14 Marketing Part One: Reducing Churn 64 Putting the Money Where the Mouse Is | Jeremy Shea Magnus Alm and Johan Peitz | Taking Icy Tower to 16 Leveraging Social Platforms as a Monetization Engine Facebook Lessons Learned 65 The Debate Over Hardcore Female Gamers | Shanna Tellerman Scott Griffiths | QA Cost Containment Strategies 21 Beginning to Bridge the Gender Gap Maximizing ROI from QA Activities 68 Getting the Scoop on Design | Rick Marazzani Greg Rahn | Fun in Soundville 24 Principles Dished Out in Your Grocer’s Freezer A Conversation about Audio for Social Games David Westendorf | Telepathy in Games 26 Bringing Brain-Computer Interface Technology to Consumers Monetization 70 Paying Can Be Fun | Simon Jones Acknowledging the Most Important Interaction Industry Business Between Seller and Buyer Susan Wu | Bringing Some WoW to FarmVille Fans 28 74 Optimizing Offers | Alex Rampell City of Eternals Breaks New Ground Three Tips to Dramatically Increase Revenues and Make Users Happy Three Guys, Five Questions 32 A Brief Conversation about Social Games 76 Making Retail Pay | Ries Derkman Publishing Casual Games Through Retail Blake Madden | We All Scream For Streams 34 New Directions in Game Distribution Technology 79 Make Them an Offer They Can’t Refuse | Janis Zech and Jan Beckers Klaus Schmidt | Sell Ideas, Not Games 36 Choosing the Offer-based Monetization Platform Eight Questions Worth Pondering .
    [Show full text]
  • Serious Games Advergaming, Edugaming, Training and More
    Serious games Advergaming, edugaming, training and more Project manager Laurent Michaud [email protected] M83708 – June 2008 Author Julian Alvarez, PhD Science of Communication and Information Contributor Laurent Michaud, Head of the digital leisure division Copyright IDATE 2008, BP 4167, 34092 Montpellier Cedex 5, France Tous droits réservés – Toute reproduction, stockage All rights reserved. None of the contents of this ou diffusion, même partiel et par tous moyens, y publication may be reproduced, stored in a retrieval compris électroniques, ne peut être effectué sans system or transmitted in any form, including accord écrit préalable de l'IDATE. electronically, without the prior written permission of IDATE. ISBN 978-2-84822-169-4 Executive Summary Serious Games Advergaming, edugaming, training and more This study outlines the characteristics, uses and different genres of serious game. It examines the challenges involved in the design, development and distribution of various types of titles, while analysing the outlook for the industry and its growth drivers. 600 million to one billion potential Defining serious gaming Areas addressed users worldwide. There is a huge variety of ways to classify Today, serious games are employed in a At the end of 2007, the global video serious gaming. However, accepting the wide variety of sectors. game industry was worth 30 billion ambiguities and possible challenges in- Defence: one of the most important USD. At the same time, the serious herent in this, this study defines serious areas in terms of client investment and gaming market was estimated to be gaming as follows: orders. Serious games are also used by worth between 1.5 and 10+ billion The purpose of a serious game is to armies in Europe, though less widely than USD.
    [Show full text]
  • Sympathoadrenergic Modulation of Hematopoiesis: a Review of Available Evidence and of Therapeutic Perspectives
    REVIEW published: 05 August 2015 doi: 10.3389/fncel.2015.00302 Sympathoadrenergic modulation of hematopoiesis: a review of available evidence and of therapeutic perspectives Marco Cosentino*, Franca Marino and Georges J. M. Maestroni Center for Research in Medical Pharmacology, University of Insubria, Varese, Italy Innervation of the bone marrow (BM) has been described more than one century ago, however the first in vivo evidence that sympathoadrenergic fibers have a role in hematopoiesis dates back to less than 25 years ago. Evidence has since increased showing that adrenergic nerves in the BM release noradrenaline and possibly also dopamine, which act on adrenoceptors and dopaminergic receptors (DR) expressed on hematopoietic cells and affect cell survival, proliferation, migration and engraftment ability. Remarkably, dysregulation of adrenergic fibers to the BM is associated with hematopoietic disturbances and myeloproliferative disease. Several adrenergic and dopaminergic agents are already in clinical use for non-hematological indications and with a usually favorable risk-benefit profile, and are therefore potential candidates for Edited by: non-conventional modulation of hematopoiesis. Wanda Lattanzi, Università Cattolica del Sacro Cuore, Keywords: dopamine, noradrenaline, adrenaline, adrenoceptors, dopaminergic receptors, hematopoiesis, Italy neuroimmune phamacology, drug repurposing Reviewed by: Sujit Basu, Introduction Ohio State University, USA Tsvee Lapidot, Weizmann Institute of Science, Israel The term ‘‘niche’’, derived from the Latin word ‘‘mytilus’’ (mussel), has eventually come to designate a shallow recess in a wall, as for a statue or other decorative object, in view of the *Correspondence: similarity with the shape of a seashell, and broadly a place suitable or appropriate for a person or Marco Cosentino, Center for Research in Medical thing.
    [Show full text]
  • The German Games Industry 2019/20
    The German games industry 2019/20 Insights, facts and reports Anno 1800, the latest instalment Editorial 4 of the renowned strategy series, is being developed in close connection Investing in the German games market 6 with the loyal Anno community. Ten good reasons for investing in the German market Federal budget includes 50 million euros for games funding for the first time Associations, networks and funding 14 German market for digital games: 16 facts and figures Germany’s developer landscape 26 Job market situation and education 30 opportunities Gaming studios and companies 32 That’s what they said: German devs 48 and industry experts about Germany’s gaming industry Esports in Germany 50 gamescom: celebrate the games 56 Education register 60 Association register 64 Company register 66 Contents 3 Dear Readers, Some 520 companies in Germany are active in the development and marketing of games, providing jobs Germany is one of the most important markets for for over 11,000 people. Universities in many large computer and video games worldwide. No European German cities also train new talent for all major areas country generates higher sales with games and the of the games industry. Germany also plays a special associated hardware. Germany’s benefits as a business role in the esports segment: some of the world’s largest location include its geographical position in the heart tournaments, the ESL One tournaments, take place of Europe and its excellent infrastructure, as well as its here. And the ESL itself, one of the most important membership in the EU and the uninhibited exchange it organisers of esports tournaments and leagues in the therefore enjoys with over half a billion people on the world, is headquartered in Germany.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,376.418 B2 Haidle Et Al
    USOO9376418B2 (12) United States Patent (10) Patent No.: US 9,376.418 B2 Haidle et al. (45) Date of Patent: Jun. 28, 2016 (54) SUBSTITUTED PYRIDINE SPLEEN 31/5377 (2013.01); A61K3I/5383 (2013.01); TYROSINE KINASE (SYK) INHIBITORS A61 K3I/551 (2013.01); A61K 45/06 (2013.01); C07D401/14 (2013.01); C07D (71) Applicants: Merck Sharp & Dohme Corp., 405/14 (2013.01); C07D 409/14 (2013.01); Rahway, NJ (US); Merck Canada Inc., C07D 413/14 (2013.01); C07D 417/14 Kirkland, Quebec (CA) (2013.01); C07D 471/04 (2013.01); (Continued) Inventors: (72) Andrew M. Haidle, Cambridge, MA (58) Field of Classification Search (US); Sandra Lee Knowles, Princeton, CPC ............... CO7D 401/12: CO7D 401/14: A61 K NJ (US); Solomon D. Kattar, Arlington, 31/5377; A61K31/506 MA (US); Denis Deschenes, Lachine USPC ........................ 544/122, 331; 514/235.8, 275 (CA); Jason Burch, Redwood City, CA See application file for complete search history. (US); Joel Robichaud, Dollard-des-Ormeaux (CA); Matthew (56) References Cited Christopher, Brookline, MA (US); Michael D. Altman, Needham, MA U.S. PATENT DOCUMENTS (US); James P. Jewell, Newtown, MA 5,710,129 A 1/1998 Lynch et al. (US); Alan B. Northrup, Reading, VA 6/2001 Uckun et al. (US); Marc Blouin, Saint-Lazare (CA); 6,248,790 B1 John Michael Ellis, Needham, MA (Continued) (US); Hua Zhou, Acton, MA (US); Christian Fischer, Natick, MA (US); FOREIGN PATENT DOCUMENTS Adam J. Schell, Decatur, GA (US); EP 877O2O A1 11, 1998 Michael H. Reutershan, Brookline, MA EP 2441755 A1 4/2012 (US); Brandon M.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Effect of Rutin on the Isolated Rat Duodenum and Comparison with the Effects of Adrenaline, Isoprenaline and Papaverine
    Ankara Ezc. Fak. Der. J. Fac. Pharm. Ankara 17, 49 (1987) 17, 49 (1987) Effect of Rutin on the Isolated Rat Duodenum and Comparison with the Effects of Adrenaline, Isoprenaline and Papaverine. Rutin'in İzole Sıçan Duodenumu Üzerine Etkisi ve Adrenalin, İzo- prenalin, Papaverin ile Karşılaştırılması. Orhan ALTINKURT* Yusuf ÖZTÜRK** SUMMARY The experiments were performed by using isolated rat duodenum. Rutin, a natural flavonoid compound, caused relaxations of the rat duodenum dose-dependently. The relaxant effect of rutin on the rat duodenum was examined in comparison with that of adrenaline, iso- prenaline and papaverine. In addition, propranolol, a beta-adrener- gic blocking agent, phentolamine, an alpha-adrenergic blockingagent and nicotinic acid, an adenyl cyclase inhibitor were used as tools to investigate mechanism of the relaxant effect of rutin on the rat duo- denum in vitro. ÖZET Deneyler izole sıçan duodenumu kullanılarak sürdürüldü. Doğal bir flavonoid bileşiği olan rutin doza bağımlı biçimde sıçan duodenu- munu gevşetti. Rutin'in sıçan duodenumundaki gevşetici etkisi ad- renalin, izoprenalin ve papaverin ile karşılaştırmalı olarak incelendi. Ayrıca, rutin'in sıçan duodenumundaki gevşetici etkisinin mekaniz- masını araştırmak için beta-adrenerjik bloker olan propranolol, alfa- adrenerjik bloker olan fentolamin ve bir adenil siklaz inhibitörü olan nikotinik asid de kullanıldı. Key words: Rutin, Adrenaline, Isoprenaline, Papaverine, Phento- lamine, Propranolol, Nicotinic acid, Smooth muscle. Rutin is found in many plants, particularly extracts from Fagopyrum esculentum, Fagopyrum cymosum, Fagopyrum tataricum Redaksiyona verildiği tarih: 19.2.1987 * Dept. Pharmacol., Fac. Pharm., Univ. Ankara. ** Dept. Pharmacol., Fac. Pharm., Univ. Anatolia. SO Orhan ALTINKURT, Yusuf ÖZTÜRK (Polygonaceae), Ruta chalepensis, Ruta graveolens (Rutaceae) and Viola tricolor, Viola lutea splendens (Violaceae).
    [Show full text]
  • Data Sheet Template
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME IsuprelTM 0.2 mg/mL Solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of the sterile 1:5000 solution contains 0.2 mg of Isoprenaline hydrochloride. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection A colourless, sterile, non pyrogenic solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Isuprel is indicated for: 1. Mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. 2. Serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia of fibrillation). (see section 4.3). 3. Use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, are available. (see section 4.3). 4. Bronchospasm occurring during anaesthesia. 5. As an adjunct to fluid and electrolyte replacement therapy and the use of other medicines and procedures in the treatment of hypovolaemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (see section 4.4). 4.2 Dose and method of administration Isuprel can be administered by the intravenous, intramuscular, subcutaneous or intracardiac routes. Isuprel should generally be started at the lowest recommended dose and the rate of administration gradually increased if necessary while carefully monitoring the patient. The usual route of administration is by intravenous infusion or bolus intravenous injection. In dire emergencies, the medicine may be administered by intracardiac injection. If time is not of the utmost importance, initial therapy by intramuscular or subcutaneous injection is preferred. Version: 4.0 Page 1 of 11 Elderly patients may be more sensitive to the effects of sympathomimetics and lower doses may be required.
    [Show full text]
  • OUH Formulary Approved for Use in Breast Surgery
    Oxford University Hospitals NHS Foundation Trust Formulary FORMULARY (Y): the medicine can be used as per its licence. RESTRICTED FORMULARY (R): the medicine can be used as per the agreed restriction. NON-FORMULARY (NF): the medicine is not on the formulary and should not be used unless exceptional approval has been obtained from MMTC. UNLICENSED MEDICINE – RESTRICTED FORMULARY (UNR): the medicine is unlicensed and can be used as per the agreed restriction. SPECIAL MEDICINE – RESTRICTED FORMULARY (SR): the medicine is a “special” (unlicensed) and can be used as per the agreed restriction. EXTEMPORANEOUS PREPARATION – RESTRICTED FORMULARY (EXTR): the extemporaneous preparation (unlicensed) can be prepared and used as per the agreed restriction. UNLICENSED MEDICINE – NON-FORMULARY (UNNF): the medicine is unlicensed and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. SPECIAL MEDICINE – NON-FORMULARY (SNF): the medicine is a “special” (unlicensed) and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. EXTEMPORANEOUS PREPARATION – NON-FORMULARY (EXTNF): the extemporaneous preparation (unlicensed) cannot be prepared and used unless exceptional approval has been obtained from MMTC. CLINICAL TRIALS (C): the medicine is clinical trial material and is not for clinical use. NICE TECHNOLOGY APPRAISAL (NICETA): the medicine has received a positive appraisal from NICE. It will be available on the formulary from the day the Technology Appraisal is published. Prescribers who wish to treat patients who meet NICE criteria, will have access to these medicines from this date. However, these medicines will not be part of routine practice until a NICE TA Implementation Plan has been presented and approved by MMTC (when the drug will be given a Restricted formulary status).
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]